On 1 October, Allergy UK and Anaphylaxis UK officially came together to form Allergy UK incorporating Anaphylaxis UK. By combining our expertise, resources, shared commitment and passionate teams, we now can create a stronger,…
Read more
2026 has been a landmark year for the allergic and anaphylactic community. From a stronger united voice for people living with allergy to major progress in schools, national policy and treatment options,…
Read more
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a lower-dose version of the adrenaline nasal spray, EURneffy®, for the emergency treatment of serious allergic reactions (anaphylaxis) in children aged four…
Read more
At the start of Allergy Awareness Week, a groundbreaking coalition of charities, clinicians and patients have united to tackle decades of policy neglect with allergic disease affecting over 25% of UK population….
Read more
Press release shared on behalf of the National Allergy Strategy Group, of which Anaphylaxis UK is a member The National Allergy Strategy Group (NASG) welcomes last night’s House of Commons debate, in…
Read more
Anaphylaxis UK (formerly The Anaphylaxis Campaign) acknowledges the findings of the Fundraising Regulator’s report and welcomes the opportunity to further strengthen communication and compliance across our fundraising activity. While the report identifies…
Read more
Benedict’s Law — the campaign to make schools safe for children with allergies — reaches a pivotal moment as peers voted on a landmark House of Lords amendment to the Children’s Wellbeing and Schools…
Read more
Anaphylaxis UK announces that Simon Williams has stepped down from his role as Chief Executive to pursue other opportunities.
Read more
A new UK study led by Imperial College London, published in Archives of Disease in Childhood, finds that providing every school with spare adrenaline auto-injectors (AAIs) could improve emergency care for children and save…
Read more